Incyte (NASDAQ:INCY) Stock Price Up 8.6% on Earnings Beat

Shares of Incyte Corporation (NASDAQ:INCY) shot up 8.6% during trading on Tuesday after the company announced better than expected quarterly earnings. The company traded as high as $128.28 and last traded at $129.1450. 2,326,434 shares changed hands during trading, an increase of 32% from the average session volume of 1,757,770 shares. The stock had previously closed at $118.87.

The biopharmaceutical company reported $3.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.20 by $0.89. Incyte had a return on equity of 26.66% and a net margin of 26.71%.The company had revenue of $1.67 billion for the quarter, compared to analysts’ expectations of $1.50 billion. During the same quarter in the prior year, the company earned $1.57 earnings per share. The firm’s revenue was up 37.7% on a year-over-year basis.

Key Incyte News

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Quarterly results topped expectations. Incyte reported second-quarter revenue of $1.67 billion, up 37.7% year over year and above the $1.50 billion consensus estimate. Adjusted EPS of $3.09 also exceeded the $2.20 consensus, compared with $1.57 a year earlier. Incyte Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Opzelura and oncology products drove growth. Opzelura sales surged 173% to $450 million, including a $246 million one-time, non-cash benefit related to the company’s CMS settlement. Hematology and oncology portfolio sales rose 69% to $222 million, while Jakafi and Jakafi XR sales increased 7% to $817 million. Opzelura and Cancer Portfolio Fuel Strong Quarter
• Positive Sentiment: Incyte raised its 2026 sales outlook. The company increased full-year total net sales guidance to approximately $5.13 billion-$5.26 billion, citing the CMS agreement and product growth. It also expects 10 clinical data readouts during the second half of 2026, providing potential catalysts. Incyte Lifts Annual Revenue Forecast
• Neutral Sentiment: Valuation and momentum remain supportive. Zacks characterized Incyte as a strong value stock, while the shares have risen substantially and trade near their 12-month high. Why Incyte Is a Strong Value Stock
• Negative Sentiment: Full-year guidance trails expectations. The $5.13 billion-$5.26 billion revenue outlook remains below the roughly $5.6 billion consensus estimate, potentially limiting upside despite the quarterly beat.
• Negative Sentiment: Pipeline and valuation concerns remain. Incyte discontinued a Phase 1 JAK inhibitor to focus on next-generation programs, reducing one development opportunity. Separately, an analyst downgraded the stock from Buy to Hold after its 93% rally, and the shares underperformed some peers despite gaining. Incyte Ditches Phase 1 JAK Inhibitor Incyte Rating Downgrade

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on INCY. UBS Group increased their price target on Incyte from $103.00 to $113.00 and gave the company a “neutral” rating in a research report on Friday, June 26th. Sanford C. Bernstein began coverage on Incyte in a report on Thursday, May 21st. They set a “market perform” rating and a $99.00 price objective on the stock. JPMorgan Chase & Co. upped their price objective on shares of Incyte from $105.00 to $110.00 and gave the company a “neutral” rating in a research note on Thursday, July 23rd. Morgan Stanley raised their target price on shares of Incyte from $103.00 to $104.00 and gave the stock an “equal weight” rating in a report on Thursday. Finally, Oppenheimer reissued a “market perform” rating and issued a $107.00 target price on shares of Incyte in a research report on Monday, June 8th. Eight analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company’s stock. According to MarketBeat, Incyte currently has an average rating of “Hold” and an average price target of $111.10.

Hedge Funds Weigh In On Incyte

Several institutional investors and hedge funds have recently modified their holdings of INCY. Toth Financial Advisory Corp bought a new position in Incyte during the fourth quarter valued at approximately $1,213,000. Universal Beteiligungs und Servicegesellschaft mbH grew its position in Incyte by 11.5% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 210,097 shares of the biopharmaceutical company’s stock worth $20,719,000 after acquiring an additional 21,735 shares in the last quarter. Twin Capital Management Inc. acquired a new position in shares of Incyte during the 1st quarter worth $875,000. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Incyte by 5,218.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 596,840 shares of the biopharmaceutical company’s stock valued at $58,950,000 after purchasing an additional 585,618 shares in the last quarter. Finally, Sector Gamma AS raised its holdings in shares of Incyte by 6.7% during the 4th quarter. Sector Gamma AS now owns 218,783 shares of the biopharmaceutical company’s stock valued at $21,609,000 after purchasing an additional 13,669 shares in the last quarter. 96.97% of the stock is currently owned by hedge funds and other institutional investors.

Incyte Stock Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.60 and a current ratio of 3.68. The firm’s 50 day moving average is $107.30 and its 200-day moving average is $101.72. The firm has a market cap of $25.58 billion, a price-to-earnings ratio of 18.15, a price-to-earnings-growth ratio of 1.06 and a beta of 0.76.

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.